Skip to content

Amber N. Edinoff

5 papers in the library · 72 citations · publishing 2022-2025

Papers

Sort Most recent Most cited

Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice—Lessons Learned from a State Underrepresented in Clinical Psychedelic Research

Psychedelic Medicine December 19, 2025 Amanda Husein, Madalynn Traylor, M. Frances Vest et al.

Background: Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. Due to the controversial nature of psilocybin, psychiatrists may not be fully prepared to incorporate it into clinical practice. The current study aimed to evaluate the opinions toward psilocybin among practicing psychiatrists in Louisiana. Louisiana...

Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability

Neurology International March 28, 2023 Amber N. Edinoff, Saveen Sall, Colby B. Koontz et al. 5 citations

While driving under the influence of drugs, drivers are more likely to be involved in and cause more accidents than drivers who do not drive under the influence. Ketamine is derived from phencyclidine and acts as a noncompetitive antagonist and allosteric modulator of N-methyl-D-aspartate receptors. Ketamine has been used to treat a variety of psychiatric disorders, with the most notable being...

Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review

Health Psychology Research October 6, 2022 Amber N. Edinoff, Natalie W. Wu, Bryce Bonin et al. 11 citations

Even as prescription opioid dispensing rates have begun to decrease, the use of illicit opioids such as heroin and fentanyl has increased. Thus, the end of the opioid epidemic is not in sight, and treating patients that are addicted to opioids remains of utmost importance. Currently, the primary pharmacotherapies used to treat opioid addiction over the long term are the opioid antagonist...

The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease

Neurology International June 23, 2022 Islam Mohammad Shehata, Waniyah Masood, Nouran Nemr et al. 41 citations

Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age. There is evidence that depression is linked to certain neurodegenerative diseases, one being Alzheimer’s disease (AD). The efficacy of conventional antidepressants to treat depression in AD is...

Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence

Neurology International May 18, 2022 Amber N. Edinoff, Juliana M. Fort, Christina Singh et al. 15 citations

With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate...